Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.61 |
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.60 |
| ▸ | MGLL | Q99685 | 2/20 | 0.60 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24042689 | 0.95 | ALDH1A1 (0.69) | ALDH1A1KDM4ELMNATSHRKMT2A | |
| SCHEMBL24042626 | 0.93 | ALDH1A1 (0.61) | ALDH1A1KDM4ELMNATSHRKMT2A | |
| SCHEMBL13504020 | 0.87 | ALDH1A1 (0.74) | ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL24042716 | 0.85 | ALDH1A1 (0.49) | ALDH1A1KDM4ELMNATSHRKMT2A | |
| SCHEMBL3702296 | 0.80 | ALDH1A1 (0.61) | ALDH1A1KDM4ELMNATSHR | |
| SCHEMBL23086075 | 0.80 | MGLL (0.72) | ALDH1A1KDM4EL3MBTL1HSD11B1MGLL | |
| SCHEMBL19227480 | 0.80 | HSD11B1 (0.64) | ALDH1A1KDM4EL3MBTL1L3MBTL3HSD11B1 | |
| SCHEMBL3776961 | 0.79 | ALDH1A1 (0.63) | ALDH1A1KDM4ELMNATSHRKMT2A | |
| SCHEMBL24123662 | 0.79 | KDM4E (0.60) | ALDH1A1KDM4EL3MBTL1L3MBTL3HSD11B1 | |
| SCHEMBL29517202 | 0.79 | KDM4E (0.60) | ALDH1A1KDM4EL3MBTL1L3MBTL3HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210361774-A1 | DEGRADERS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-25 | — | — | US | disclosed |
| EP-2699572-B1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210361774-A1 | DEGRADERS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | LRRK2, CLK2, DDRGK1 | ALDH1A1 3589/4885KDM4E 1865/4885LMNA 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.